More options for patients with valve disease
At The Christ Hospital, we offer a comprehensive range of minimally invasive surgeries for patients with simple and complex valve disease. Our team of dedicated physicians and clinicians have extensive experience in diagnosing and treating aortic, mitral, pulmonary, and bicuspid and tricuspid valve diseases, and are devoted to improving the quality of life for our heart valve disease patients.
It's this dedication to exceptional patient care that has given our patients the best outcomes with the least invasive procedures possible. Patients at The Christ Hospital with an isolated valve issue (aortic, mitral or tricuspid) are 85 percent more likely to have a minimally invasive procedure versus a traditional open operation.
In fact, our heart valve disease experts offer the latest treatments not found at other hospitals in our region.
Minimally invasive aortic valve repair and replacement options
Our physicians were pioneers in the development of transcatheter aortic valve replacement (TAVR) and we were the first hospital in the region to offer this minimally invasive option to patients. Our team has more experience with TAVR than any other hospital in the region, performing almost 900 TAVR procedures for symptomatic aortic stenosis. This is critical since physicians and hospitals with higher volumes of the TAVR procedure mean better outcomes for patients, including lower mortality. (American College of Cardiology Scientific Sessions, 2016).
The Christ Hospital is the only hospital in the region able to offer this life-saving procedure to all aortic valve patients.
Until recently, TAVR has only been available to about 40 percent of patients with aortic valve disease - those who are at extreme, high or moderate risk for complications from surgical valve replacement (SAVR). Because of our extensive experience with the TAVR procedure and the reputation of the Linder Research Center and our physicians, The Christ Hospital was chosen as a clinical trial site by Medtronic and Boston Scientific to expand TAVR to low-risk patients - which now gives all patients the option of a minimally invasive procedure.
Minimally invasive mitral valve repair and replacement options
Minimally invasive mitral valve repairs and replacements are another treatment option only offered at The Christ Hospital. We launched our program three years ago and our surgeons have performed more than 175 of these mitral valve repairs and replacements. The minimally invasive approach involves doing mitral valve surgeries with only a 1.5-inch incision. That's why these surgeries require the complex, skill-intensive techniques only available at The Christ Hospital in this region. With a commitment to repairing the valve versus replacing it, the physicians of The Christ Hospital are able to repair 92 percent of valves caused by degenerative mitral valve disease in their patients.
Dr. Castillo-Sang was the first cardiothoracic surgeon in the Tristate region to perform a transcatheter mitral valve replacement (TMVR) as part of the hospital’s participation in the APOLLO trial. The randomized clinical study is the first to evaluate TMVR for patients with severe symptomatic mitral regurgitation. Once again, pioneering the way to give patients with even the most complex valve disease the opportunity for a minimally invasive procedure and better outcomes.
Interventionist and surgeons at The Christ Hospital who specialize in minimally invasive valve repair surgeries also provide the treatment options below, not available anywhere else in the region:
J Valve TF System Trial – The Christ Hospital was the first in the US to successfully treat a patient with the first of its kind transfemoral TAVR device. J Valve is a new catheter-based option for treatment of patients with severe aortic regurgitation, which currently is the indication for 20-30 percent of open heart valve replacements. This is the only minimally invasive option for patients too sick to undergo open surgical repair. The J Valve has a proprietary anchor mechanism linked to a self-expanding stent frame that attaches to the failing native heart valve and does not require calcification of the native valve for fixation. The J Valve is designed to help restore normal blood flow out of the heart and into the body which may reduce or improve symptoms of heart failure, such as shortness of breath, chest pain, and fatigue.
Lotus Edge Valve - REPRISE IV is a prospective, multicenter, single-arm clinical study to assess the safety and effectiveness of transcatheter aortic valve replacement (TAVR) with the LOTUS Edge™ Aortic Valve System for intermediate surgical risk patients, including those with a bicuspid valve. The study is expected to include more than 800 patients at up to 50 sites across the U.S. (49) and Australia (1). The intent of the trial is to show how the LOTUS Edge valve performs in terms of paravalvular leaking (PVL), stroke and all-cause mortality 1 year post procedure
Edwards Bicuspid Valve for Low Risk Patients
Boston Scientific Bicuspid Valve Trial
To learn more about these trials call our Valve Nurse Navigator at 513-206-1222.
Contact our team
To learn more about our Valve Center of Excellence, please contact a member of our staff.
Stephanie May, RN - Structural Heart/Mitra Clip Coordinator, 513-206-1179
Jennifer Baker, MSN, RN - Structural Heart/Watchman Coordinator, 513-206-1188
Brigid Malone, MSN, NP-C - Structural Heart Nurse Practitioner, 513-206-1112
Ronda Evans - Senior Schedular, 513-206-1216
Samantha Huber - Schedular, 513-206-1167